WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 14, 2006--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) will participate in the Roth Capital Partners 18th Annual O.C. Conference on February 21, 2006 in Dana Point, California. The Company's President and CEO, Steven Rauscher, will provide an overview of the Company including details on the recent sublicense of FACTIVE(R) (gemifloxacin mesylate) tablets in Mexico to Pfizer, S.A. de C.V and the acquisition of expanded worldwide rights for the Company's lead clinical candidate, Ramoplanin.
